Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Relacorilant (CORT125134) in Healthy Subjects
NCT06094790Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- May 2017
- Primary completion
- Nov 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of relacorilant in Cushing's syndrome (4 cohorts), sponsored by Corcept Therapeutics. Primary endpoints: Area under the concentration-time curve over a dose-interval at Day 14, Maximum concentration at Day 14 and 1 more. Started May 2017; status: completed.
02
Drugs
relacorilant
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on NCT06094790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06094790.